Trichomegaly Induced by Cetuximab: Case Series and Review the Literature

被引：8

作者：

Koksal, Ulkuhan I. ^{[1
]}

Pilanci, Kezban N. ^{[1
]}

Ordu, Cetin ^{[1
]}

Okutur, Kerem ^{[1
]}

Saglam, Sezer ^{[1
]}

Demir, Gokhan ^{[1
]}

机构：

[1] Bilim Univ, Dept Med Oncol, Fac Med, Bedrettin Mah Bedii Gorbon Sk 1 Sishane, TR-34440 Istanbul, Turkey

来源：

AMERICAN JOURNAL OF THERAPEUTICS | 2016年 / 23卷 / 05期

关键词：

cetuximab; trichomegaly; colorectal carcinoma; EYELASHES FOLLOWING TREATMENT; ELONGATION;

D O I：

10.1097/MJT.0000000000000189

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Trichomegaly is a rare side effect of epidermal growth factor receptor inhibitors. We present here 4 patients who treated with cetuximab (an epidermal growth factor receptor inhibitor) for metastatic colorectal cancer. All of the cases were treated with cetuximab 500 mg/m(2) biweekly in combination protocol. The mean period from the start of the treatment until the development the trichomegaly was 4.75 (3-6) months. In all of the patients after the end of the cetuximab therapy, trichomegaly was regressed. Only 1 case resolved with topical treatment that conjunctivitis with trichomegaly. Trichomegaly is an important ocular toxicity of cetuximab that can cause visual discomfort and corneal damages. However, these side effects usually do not require discontinuation of treatment.

引用

页码：E1226 / E1229

页数：4